Correspondence in response to paper by Thomas, M. et al. 2021: Predicting the EQ-5D from the Kansas City Cardiomyopathy Questionnaire (KCCQ) in patients with heart failures

Online publish-ahead-of-print 29 April 2021

We congratulate Thomas et al.1 for developing algorithms mapping Kansas City Cardiomyopathy Questionnaire (KCCQ) to EQ-5D health-utility scores for patients with heart failure (HF). EQ-5D is a standard tool for assessing cost-effectiveness (QALYs) across disease areas. However, such generic health-utility measures may fail to capture key health states relevant to heart failure (such as breathlessness and fatigue). There is a need for disease-specific utility measure for heart failure.2

Mapping disease-specific, patient-reported outcomes like KCCQ to EQ-5D has limitations, as the authors acknowledge.1 However, the potential insensitivity of EQ-5D to changes in health state should be considered.2–4

EQ-5D may be sensitive to the effects of interventions in advanced heart failure (New York Heart Association (NYHA) III-IV), but perhaps less so for milder disease.4,5

Thomas et al. used EuroQol-5 Dimension (EQ-5D) data from the HF-ACTION trial (n = 2331 HF patients) but do not mention that no difference was observed at 12 months in either EQ-5D index score or visual analogue scale (VAS) with exercise-based rehabilitation compared with control (VAS: Rehab: 1 ± 17 vs. control: 2 ± 17; P = 0.15).3 Was the intervention ineffective or was the tool insensitive to change? Mapping KCCQ to a tool that is not sensitive to change could undervalue the effects of the intervention.

Conflict of interest: none declared.

References

Hasnain Dalal1,2*, Rod S Taylor1,3, and John G. Cleland3

1Primary Care Research Group, University of Exeter, Exeter, UK; 2Knowledge Spa, Royal Cornwall Hospitals NHS Trust Truro TR1 3HD, UK and 3MRC/CSO Social and Public Health Sciences Unit & Robertson Centre for Biostatistics, University of Glasgow, Glasgow, UK

* Corresponding author. Tel: +447974818345; Email: h.dalal@nhs.net